Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as it faces pressure from activist hedge fund Starboard Value.

Starboard’s stake comes amid a time of struggle at the drugmaker, which has begun to cut costs aggressively as demand for its Covid-19 medicines recedes.

Activist investor Starboard Value accused Pfizer of pressuring its former CEO Ian Read and ex-CFO Frank D’Amelio to halt support for Starboard’s turnaround campaign. Starboard’s Jeff Smith revealed the company allegedly threatened to claw back compensation and cancel unvested shares.

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the U.S. drugmaker to investigate actions by its board, after two former executives backed out of its campaign against the company.

Activist investor Starboard Value claims the pharma giant’s former CEO and CFO were “threatened” into backing current management.

As the battle over Pfizer’s future continues, former executives said they would no longer support activist investor Starboard Value.

Pfizer CEO Albert Bourla reportedly is planning to meet with Starboard Value after the activist investor took a $1 billion stake in the struggling drugmaker.

Starboard has accused Pfizer of “coercive conduct” after executives who initially backed the hedge fund retracted their support.